Biologics Attenuate Radiographic Progression over 2-Year Period in Patients with Axial Spondyloarthritis

Latest Data on JAK Inhibitors Prove Promising in Ankylosing Spondylitis

IL-17 Inhibitor Demonstrates Efficacy in Pediatric Counterparts of
nr-axSpA and PsA

Long-term Control of Rheumatoid Arthritis: Oral Targeted Agent Shows Sustained Advantage Over Biologic

Novel JAK Inhibitor Shows Efficacy over 48 Weeks of Treatment for Long-Term Control of Rheumatoid Arthritis

Oral JAK Inhibitors May Displace Injectable Biologics in Treatment of Rheumatoid Arthritis

Patient Support Program Helps Sustain Low Disease Activity on TNF Inhibitor Therapy

bDMARDs Improve Vascular Function in Treatment-naïve Patients with Early Rheumatoid Arthritis

Early Knee, Jaw, Wrist, or Elbow Swelling Associated with Worse Rheumatoid Arthritis Prognosis

Emerging Options: Moving Toward JAK1 Selectivity in Rheumatoid Arthritis

Expansion in Biologic Option Critical For Non-Responders to TNF Inhibitors

Frequency at which Target Serum Urate Levels Are Missed in Gout is Prompting Strategy Modifications